Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
JP Morgan initiated coverage on Novavax, Inc. (NASDAQ: NVAX) with an Overweight rating and $7 price target.
Analyst Cory Kasimov noted that he is "impressed by the potential of the company’s proprietary recombinant nanoparticle vaccine technology" and he believed that "the platform has been validated by clinical data."
According to the company, Novavax has created a portfolio of "novel vaccines that represent important advances over existing vaccines or that address currently unmet medical needs, to prevent human infectious diseases."
Among the vaccine portfolio is an H7N9 Avian Influenza VLP vaccine, which recently showed positive results in clinical trials.
Novavax, Inc. recently traded at $4.50, up 7.13 percent.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!